<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: December ", fill: "#872657"},
{source: "4: December ", target: "4: accumulated deficit", fill: "#872657"},
{source: "4: accumulated deficit", target: "4: approximately", fill: "#872657"},
{source: "4: December ", target: "11: significant clinical", fill: "#d40000"},
{source: "11: significant clinical", target: "11: acceptance", fill: "#d40000"},
{source: "11: acceptance", target: "11: direct sales strategy", fill: "#d40000"},
{source: "11: direct sales strategy", target: "11: adversely affected", fill: "#d40000"},
{source: "11: significant clinical", target: "13: December ", fill: "#f4c2c2"},
{source: "13: December ", target: "13: significant", fill: "#f4c2c2"},
{source: "13: significant", target: "13: successfully", fill: "#f4c2c2"},
{source: "13: successfully", target: "13: operations", fill: "#f4c2c2"},
{source: "13: December ", target: "31: governmental", fill: "#796878"},
{source: "31: governmental", target: "31: financial condition", fill: "#796878"},
{source: "31: financial condition", target: "31: operations", fill: "#796878"},
{source: "31: governmental", target: "37: existing rules", fill: "#addfad"},
{source: "37: existing rules", target: "37: regulations", fill: "#addfad"},
{source: "37: regulations", target: "37: agencies may", fill: "#addfad"},
{source: "37: agencies may", target: "37: adversely impact", fill: "#addfad"},
{source: "37: adversely impact", target: "37: manufacture", fill: "#addfad"},
{source: "37: existing rules", target: "118: sufficient intellectual property protection", fill: "#0047ab"},
{source: "118: sufficient intellectual property protection", target: "118: competitors may", fill: "#0047ab"},
{source: "118: competitors may", target: "118: sell products identical", fill: "#0047ab"},
{source: "118: sell products identical", target: "118: downward pressure on", fill: "#0047ab"},
{source: "118: downward pressure on", target: "118: selling price", fill: "#0047ab"},
{source: "118: sufficient intellectual property protection", target: "129: stockholders equity may also", fill: "#cf0"},
{source: "129: stockholders equity may also", target: "129: adversely affected by unfavorable", fill: "#cf0"},
{source: "129: adversely affected by unfavorable", target: "129: translation adjustments", fill: "#cf0"},
{source: "129: translation adjustments", target: "129: from differences", fill: "#cf0"},
{source: "129: from differences", target: "129: exchange rates from", fill: "#cf0"},
{source: "129: stockholders equity may also", target: "149: average trading volume", fill: "#b0e0e6"},
{source: "149: average trading volume", target: "149: common stock", fill: "#b0e0e6"},
{source: "149: common stock", target: "149: relatively low", fill: "#b0e0e6"},
{source: "149: relatively low", target: "149: most larger companies", fill: "#b0e0e6"},
{source: "149: average trading volume", target: "150: volatility", fill: "#966fd6"},
{source: "150: volatility", target: "151: common stock", fill: "#fe28a2"},
{source: "151: common stock", target: "151: been traded publicly since", fill: "#fe28a2"},
{source: "151: been traded publicly since", target: "151: February ", fill: "#fe28a2"},
{source: "151: February ", target: "151: few market makers", fill: "#fe28a2"},
{source: "151: common stock", target: "154: market price", fill: "#00ff7f"},
{source: "154: market price", target: "154: common stock", fill: "#00ff7f"},
{source: "154: common stock", target: "154: highly volatile", fill: "#00ff7f"},
{source: "154: market price", target: "START_HERE", fill: "#00ff7f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Household Products</td>
    </tr>
    <tr>
      <td>Personal Products</td>
    </tr>
    <tr>
      <td>Leisure Products</td>
    </tr>
    <tr>
      <td>Paper Products</td>
    </tr>
    <tr>
      <td>Household and Personal Products</td>
    </tr>
    <tr>
      <td>Building Products</td>
    </tr>
    <tr>
      <td>Agricultural Products</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>I FLOW CORP /DE/      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>RISK FACTORS RELATING TO OUR BUSINESS AND THE INDUSTRY IN WHICH WE OPERATE     We have experienced net losses in <font color="blue">prior periods</font> and have an <font color="blue">accumulated</font>     deficit</td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December </font>31,  2005,  our <font color="blue">accumulated</font> deficit was <font color="blue">approximately</font>     dlra40dtta6 million</td>
    </tr>
    <tr>
      <td>We had net income (losses) of (dlra8dtta4 million), (dlra17dtta1 million)     and dlra0dtta5 million for the years ended <font color="blue">December </font>31, 2005, 2004 and 2003,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We may not achieve or maintain <font color="blue">profitability</font> in the future,     and <font color="blue">further losses may</font> arise</td>
    </tr>
    <tr>
      <td>For example, during the year ended <font color="blue">December </font>31, 2004, our total costs and     <font color="blue">expenses increased by</font> an <font color="blue">amount <font color="blue">greater than</font></font> the increase in revenues,     compared to the year ended <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>There can be no assurance that     our <font color="blue">future revenue growth</font>, if any, will be <font color="blue">greater than</font> the growth of our     costs  and  expenses</td>
    </tr>
    <tr>
      <td>We have invested substantial <font color="blue">resources into</font> the sales and marketing of the     ON-Q PainBuster</td>
    </tr>
    <tr>
      <td>If this product does not achieve <font color="blue"><font color="blue">significant</font> clinical</font>     <font color="blue">acceptance</font> or if our <font color="blue">direct <font color="blue">sales strategy</font></font> is not successful, our financial     condition and operating results will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current strategy</font> assumes that the ON-Q PainBuster will be used in a     <font color="blue">significant</font> number of surgical cases, ultimately becoming the standard of     care for many <font color="blue">common procedures</font></td>
    </tr>
    <tr>
      <td>We have invested, and continue to invest, a     substantial portion of our resources to establish and maintain a direct     sales force to sell and market ON-Q During the year ended <font color="blue">December </font>31,     2005, we invested <font color="blue">approximately</font> dlra48dtta8 million in the sales and marketing of     ON-Q  A  failure of ON-Q to achieve and maintain a <font color="blue">significant</font> market     presence,  or  the  failure to <font color="blue">successfully</font> implement our direct sales     strategy, will have a material adverse effect on our <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>8       _________________________________________________________________    [40]Table of <font color="blue">Contents       </font>Our <font color="blue">customers <font color="blue">frequently</font></font> receive <font color="blue"><font color="blue">reimbursement</font> from <font color="blue">private insurers</font></font> and     <font color="blue"><font color="blue">governmental</font> agencies</font></td>
    </tr>
    <tr>
      <td>Any change in the <font color="blue">overall <font color="blue"><font color="blue">reimbursement</font> system</font> may</font>     <font color="blue"><font color="blue">adversely</font> impact</font> our business</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">health care</font> <font color="blue"><font color="blue">reimbursement</font> system</font></font> is in a constant state of change</td>
    </tr>
    <tr>
      <td>Changes often create <font color="blue">financial incentives</font> and <font color="blue">disincentives</font> that encourage     or discourage the use of a particular type of product, therapy or clinical     procedure</td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> and sales of our <font color="blue">products may</font> be <font color="blue">adversely</font>     <font color="blue">affected by</font> changes or <font color="blue">trends within</font> the <font color="blue"><font color="blue">reimbursement</font> system</font></td>
    </tr>
    <tr>
      <td>Changes to     the <font color="blue">health care</font> system that favor <font color="blue">technologies</font> other than ours or that     reduce <font color="blue"><font color="blue">reimbursement</font>s</font> to providers or treatment <font color="blue">facilities</font> that use our     <font color="blue">products may</font> <font color="blue">adversely</font> affect our ability to sell our products profitably</td>
    </tr>
    <tr>
      <td>Hospitals,  alternate  care  <font color="blue">site providers</font> and physicians are heavily     <font color="blue"><font color="blue">dependent on</font> payment</font> for their <font color="blue">services by <font color="blue">private insurers</font></font> and <font color="blue">governmental</font>     agencies</td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue"><font color="blue">reimbursement</font> system</font> could <font color="blue">adversely</font> affect our     <font color="blue">participation</font> in the industry</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products fall into</font> the general category     of  infusion  devices  and  related <font color="blue">disposable products with</font> regard to     <font color="blue"><font color="blue">reimbursement</font> issues</font></td>
    </tr>
    <tr>
      <td>Except for payments made to our <font color="blue">InfuSystem </font>subsidiary,     the majority of <font color="blue"><font color="blue">reimbursement</font>s</font> are not <font color="blue">paid directly</font> to us</td>
    </tr>
    <tr>
      <td>Rather, health     <font color="blue">care providers will often request</font> that their patients’ health insurance     <font color="blue">providers provide them with</font> some form of <font color="blue">reimbursement</font> for the <font color="blue">disposables</font>     that are consumed in the patients’ therapy</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">current trend</font> in the insurance industry (both private     and <font color="blue">governmental</font>) has been to eliminate cost-based <font color="blue">reimbursement</font> and to move     towards fixed or limited fees for service, thereby encouraging <font color="blue">health care</font>     providers to use the <font color="blue">lowest cost method</font> of delivering <font color="blue">medications</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">trend may discourage</font> the use of our products, create <font color="blue">downward pressure on</font>     our <font color="blue">average prices</font>, and, ultimately, <font color="blue">negatively</font> affect our revenues</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">reimbursement</font> rates may <font color="blue"><font color="blue">adversely</font> impact</font> InfuSystem’s revenues</td>
    </tr>
    <tr>
      <td>Our wholly owned subsidiary, InfuSystem, depends primarily on third-party     <font color="blue">reimbursement</font>  for  the <font color="blue">collection</font> of its revenues</td>
    </tr>
    <tr>
      <td><font color="blue">InfuSystem </font>is paid     <font color="blue">directly by <font color="blue">private insurers</font></font> and <font color="blue"><font color="blue">governmental</font> agencies</font>, often on a fixed fee     basis,  for  infusion  services  provided  by  <font color="blue">InfuSystem </font>to patients</td>
    </tr>
    <tr>
      <td>InfuSystem’s oncology revenues comprised 28prca of our <font color="blue">consolidated revenues</font>     for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>If the average fees allowable by     <font color="blue">private insurers</font> or <font color="blue"><font color="blue">governmental</font> agencies</font> were reduced, the negative impact     on  revenues of <font color="blue">InfuSystem </font>could have a material adverse effect on our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">reimbursement</font> rates may <font color="blue"><font color="blue">adversely</font> impact</font> the revenue that we earn     from our developing billing strategy for ON-Q     Historically, we have <font color="blue">charged <font color="blue">health care</font> providers</font> for each ON-Q unit that     they  purchase  from us</td>
    </tr>
    <tr>
      <td>Currently, in many instances, we, through our     <font color="blue">InfuSystem </font> subsidiary,  bill  <font color="blue">private insurers</font> for the use of ON-Q in     <font color="blue">ambulatory</font> surgery centers, rather than charging these centers for the     <font color="blue">purchase price</font> of each ON-Q unit</td>
    </tr>
    <tr>
      <td>If this <font color="blue">sales strategy</font> is successful, we     expect to increase our use of this <font color="blue">sales strategy</font> for <font color="blue">ambulatory</font> surgery     centers</td>
    </tr>
    <tr>
      <td>Any reduction in the average fees allowable by <font color="blue">private insurers</font> for     the use of ON-Q in <font color="blue">ambulatory</font> surgery centers could <font color="blue">negatively</font> affect our     ability to generate <font color="blue">revenue from</font> the centers and this could have a material     adverse effect on our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">highly <font color="blue">regulated by</font></font> a number of <font color="blue"><font color="blue">governmental</font> agencies</font></td>
    </tr>
    <tr>
      <td>Any     changes  to  the  <font color="blue">existing rules</font> and <font color="blue">regulations</font> of these <font color="blue">agencies may</font>     <font color="blue"><font color="blue">adversely</font> impact</font> our ability to <font color="blue">manufacture</font> and market our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> are <font color="blue">regulated by</font> the Food, Drug and Cosmetic Act</td>
    </tr>
    <tr>
      <td>Under the     Act, we are required, among other matters, to register our <font color="blue">facilities</font> and to     list  our <font color="blue">devices with</font> the FDA, to file notice of our intent to market     certain new products under Section 510(k) of the Food, Drug and Cosmetic     Act, to track the location of certain of our products, and to report any     <font color="blue">incidents</font> of death or <font color="blue">serious injury</font> relating to our products</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">comply with</font> any of these <font color="blue">regulations</font>, or if the FDA <font color="blue">subsequently disagrees</font>     with the manner in which we sought to <font color="blue">comply with</font> these <font color="blue">regulations</font>, we     could be subjected to substantial civil and <font color="blue">criminal penalties</font> and a recall,     seizure,  or <font color="blue">injunction with respect</font> to the <font color="blue">manufacture</font> or sale of our     products</td>
    </tr>
    <tr>
      <td>Each state also has similar <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>For example, in California, we are     subject to annual production-site inspections in order to maintain our     <font color="blue"><font color="blue">manufacturing</font> license</font></td>
    </tr>
    <tr>
      <td>State <font color="blue">regulations</font> also specify standards for the     storage                                         9       _________________________________________________________________    [41]Table of <font color="blue">Contents       </font>and handling of certain <font color="blue">chemicals</font> and disposal of their wastes</td>
    </tr>
    <tr>
      <td>We are also     required to <font color="blue">comply with</font> federal, state, and <font color="blue">local environmental laws</font></td>
    </tr>
    <tr>
      <td>Our     failure  to  <font color="blue">comply with</font> any of these <font color="blue">laws could expose us</font> to material     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Products  </font>intended  for  export are subject to <font color="blue">additional</font> <font color="blue">regulations</font>,     including  compliance  with  ISO  13485</td>
    </tr>
    <tr>
      <td>We  first received ISO 13485     <font color="blue">certification</font> in July 2000, which indicates that our <font color="blue">products meet specified</font>     <font color="blue">uniform standards</font> of quality and testing</td>
    </tr>
    <tr>
      <td>In 2005, we achieved ISO 13485     <font color="blue">certification</font> under the 2003 revision of the standard</td>
    </tr>
    <tr>
      <td>We have also been     granted  <font color="blue">permission</font> to use the CE mark on our products, which reflects     approval of our products for <font color="blue">export into</font> the 28 member countries of the     <font color="blue">European Community</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">certification</font> and <font color="blue">permission</font> to use the CE mark on     our <font color="blue">products also apply</font> to the <font color="blue">Block Medical </font><font color="blue">operations</font>, including its     Mexico <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> these <font color="blue">additional</font> <font color="blue">regulations</font> could     result in our <font color="blue">inability</font> to export products to the <font color="blue">European Community</font></td>
    </tr>
    <tr>
      <td>Furthermore, federal, state, local or foreign governments may enact new     laws,  rules  and <font color="blue">regulations</font> that may <font color="blue"><font color="blue">adversely</font> impact</font> our ability to     <font color="blue">manufacture</font> and <font color="blue">market <font color="blue">infusion devices</font> by</font>, for example, increasing our     costs</td>
    </tr>
    <tr>
      <td>Any <font color="blue">impairment</font> of our ability to market our <font color="blue">infusion devices</font> or other     <font color="blue">products could</font> have a material adverse effect on our <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">compliance with laws <font color="blue">frequently</font> involves</font> our <font color="blue">subjective judgment</font></td>
    </tr>
    <tr>
      <td>If we     are wrong in any of our <font color="blue">interpretations</font> of the laws, we could be subjected     to substantial penalties for <font color="blue">noncompliance</font></td>
    </tr>
    <tr>
      <td>In the ordinary course of business, <font color="blue">management</font> <font color="blue">frequently</font> makes subjective     judgments with respect to complying with the Food, Drug and Cosmetic Act, as     well as other applicable state, local and <font color="blue">foreign laws</font></td>
    </tr>
    <tr>
      <td>If any of these     <font color="blue">regulatory agencies disagrees with</font> our interpretation of, or objects to the     manner in which we have attempted to <font color="blue">comply with</font>, the <font color="blue">applicable law</font>, we     could be subjected to substantial civil and <font color="blue">criminal penalties</font> and a recall,     seizure  or  <font color="blue">injunction with respect</font> to the <font color="blue">manufacture</font> or sale of our     products</td>
    </tr>
    <tr>
      <td>These types of <font color="blue">actions against us</font> or our <font color="blue">products could</font> have a     material  adverse  effect  on  our  <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may  need  to  raise  <font color="blue">additional</font> capital in the future to fund our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">raise funds</font> when needed or on acceptable     terms</td>
    </tr>
    <tr>
      <td>During the year ended <font color="blue">December </font>31, 2005, our operating <font color="blue">activities</font> used cash     of dlra5dtta9 million and our investing <font color="blue">activities</font> provided cash of dlra11dtta7 million</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had cash and <font color="blue">equivalents</font> of dlra13dtta9 million,     short-term investments of dlra13dtta3 million and <font color="blue">net accounts receivable</font> of     dlra22dtta3 million</td>
    </tr>
    <tr>
      <td>We  believe  our current funds, together with possible     <font color="blue">additional</font> borrowings on our <font color="blue">existing lines</font> of credit and other <font color="blue">bank loans</font>,     are sufficient to provide for our projected needs to maintain <font color="blue">operations</font> for     at least the next 12 months</td>
    </tr>
    <tr>
      <td>This estimate, however, is <font color="blue">based on <font color="blue">assumptions</font></font>     that may prove to be wrong</td>
    </tr>
    <tr>
      <td>If our <font color="blue">assumptions</font> are wrong or if we experience     further  losses,  we  may be required to reduce our <font color="blue">operations</font> or seek     <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">additional</font>  equity  <font color="blue">financings</font>  may  be  dilutive to our existing     <font color="blue">stockholders</font> and involve the issuance of securities that may have rights,     <font color="blue">preferences</font> or <font color="blue">privileges senior</font> to those of our current <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>A     <font color="blue">debt financing</font>, if available, may involve restrictive covenants on our     business that <font color="blue">could limit</font> our operational and <font color="blue">financial flexibility</font>, and the     amount of <font color="blue">debt incurred could</font> make us more vulnerable to <font color="blue">economic downturns</font>     or <font color="blue">operational <font color="blue"><font color="blue">difficult</font>ies</font></font> and limit our ability to compete</td>
    </tr>
    <tr>
      <td>Furthermore,     financing  may  not  be  available when needed and may not be on terms     acceptable to us</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">intangible asset</font>s</font> are subject to potential <font color="blue">impairment</font> charges that could     <font color="blue">adversely</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, dlra2dtta6 million of our <font color="blue">assets consisted</font> of goodwill,     an <font color="blue">intangible asset</font> acquired through the <font color="blue">acquisition</font> of InfuSystem</td>
    </tr>
    <tr>
      <td>The     <font color="blue">determination</font> of the value of <font color="blue"><font color="blue">intangible asset</font>s</font> requires <font color="blue">management</font> to make     estimates and <font color="blue">assumptions</font> that affect our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>For example,     we review the <font color="blue">recoverability</font> of the carrying value of goodwill on an annual     basis or more <font color="blue">frequently</font> if an event occurs or <font color="blue">circumstances</font> change to     indicate that an <font color="blue">impairment</font> of goodwill has possibly occurred</td>
    </tr>
    <tr>
      <td>We compare     the <font color="blue">fair value</font> of our reporting units to book value, as well as consider     other factors, to determine whether or not any potential <font color="blue">impairment</font> of     goodwill exists</td>
    </tr>
    <tr>
      <td>In fiscal year 2002, as a result of the adoption of SFAS     Nodtta 142, Goodwill and Other Intangible Assets, <font color="blue">effective</font> January 1, 2002, we     wrote-off dlra3dtta5 million of goodwill related to past <font color="blue">acquisition</font>s other than     InfuSystem</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________    [42]Table of <font color="blue">Contents       </font>We <font color="blue">cannot guarantee</font> that there will be no <font color="blue">additional</font> <font color="blue">impairment</font> in the     future  related to <font color="blue">InfuSystem </font>or other <font color="blue">acquisition</font>s we may make in the     future</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">impairment</font>  charge  will <font color="blue">adversely</font> affect our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our industry is <font color="blue">intensely competitive</font> and changes rapidly</td>
    </tr>
    <tr>
      <td>If we are unable     to  maintain  a  <font color="blue"><font color="blue">technological</font> lead over</font> our <font color="blue">competitors</font>, our business     <font color="blue">operations</font> will suffer</td>
    </tr>
    <tr>
      <td>The  drug  <font color="blue">infusion industry</font> is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>We compete in this     industry based primarily on price, service and <font color="blue">product performance</font></td>
    </tr>
    <tr>
      <td>Some of     our <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater resources than we do for research     and <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing and sales</td>
    </tr>
    <tr>
      <td>We continue our efforts to <font color="blue">introduce clinically</font>     <font color="blue">effective</font>, cost-efficient products into the market, but the industry is     subject to <font color="blue">technological</font> changes and we may not be able to maintain any     existing <font color="blue">technological</font> advantage long enough to establish our products and     to achieve or sustain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">effective</font>ly compete     in  our market, our <font color="blue">financial condition</font> and results of <font color="blue">operations</font> will     <font color="blue">materially suffer</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">rely on independent suppliers</font> for parts and <font color="blue">materials necessary</font> to     assemble our products</td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">disruption</font> in the supply of parts may     prevent  us  from <font color="blue">manufacturing</font> our products and <font color="blue">negatively</font> impact our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we perform <font color="blue">final assembly</font> and testing of our completed infusion     systems, certain component parts, as well as molded products, are obtained     <font color="blue">from outside vendors based on</font> our <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>The loss or <font color="blue">breakdown</font> of     our <font color="blue"><font color="blue">relationship</font>s with</font> these <font color="blue">outside vendors could</font> subject us to substantial     delays in the delivery of our products to customers</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delays in     the delivery of our <font color="blue">products could</font> result in <font color="blue">possible cancellation</font> of orders     and  the loss of customers</td>
    </tr>
    <tr>
      <td>Furthermore, we have <font color="blue">numerous suppliers</font> of     <font color="blue">components</font> and materials that are sole-source suppliers</td>
    </tr>
    <tr>
      <td>Because these     suppliers are the <font color="blue">only vendors with which</font> we have a <font color="blue">relationship</font> for that     particular component or material, we may be unable to produce and sell     products if one of these <font color="blue">suppliers becomes unwilling</font> or unable to deliver     <font color="blue">components</font>  or  <font color="blue">materials meeting</font> our <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to     <font color="blue">manufacture</font>  and <font color="blue">sell products</font> to <font color="blue">meet delivery schedules could</font> have a     material adverse effect on our reputation in the industry, as well as our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our success in the <font color="blue">Oncology Infusion Services </font>market is <font color="blue">impacted by</font> the     <font color="blue">availability</font> of the <font color="blue"><font color="blue">chemotherapy</font> drugs</font> that are used in our <font color="blue">infusion pump</font>     systems</td>
    </tr>
    <tr>
      <td>InfuSystem,  our subsidiary that operates within the Oncology Infusion     Services market, derives its <font color="blue">revenue from</font> the rental of <font color="blue">ambulatory</font> infusion     <font color="blue">pump systems</font> to <font color="blue">oncology offices</font> and <font color="blue"><font color="blue">chemotherapy</font> clinics</font></td>
    </tr>
    <tr>
      <td>A shortage in the     <font color="blue">availability</font>  of <font color="blue"><font color="blue">chemotherapy</font> drugs</font> that are used in the <font color="blue">infusion pump</font>     systems, including a commonly-used <font color="blue">chemotherapy</font> drug known as 5-flourouracil     (“5-FU”), could have a material adverse effect on our <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For instance, we believe a shortage of 5-FU in     the <font color="blue">fourth quarter</font> of 2005 resulted in an <font color="blue">unfavorable revenue impact</font> of     <font color="blue">approximately</font> dlra1dtta9 million</td>
    </tr>
    <tr>
      <td>Because the <font color="blue">availability</font> of 5-FU is expected to     be below normal for the near term, we anticipate the <font color="blue">negative impact on</font>     revenue  to  continue  <font color="blue">at least into</font> the <font color="blue">first quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>If the     <font color="blue">availability</font> of 5-FU does not return to normal, or if there are shortages in     other commonly-used <font color="blue"><font color="blue">chemotherapy</font> drugs</font>, our revenue could continue to be     <font color="blue">negatively</font> impacted in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> the majority of our products in Mexico</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">difficult</font>ies</font> or     <font color="blue">disruption</font>s  in  the  operation  of our plant may <font color="blue"><font color="blue">adversely</font> impact</font> our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The  majority  of  our  products are <font color="blue">manufacture</font>d by our <font color="blue">Block Medical </font>    subsidiary</td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue"><font color="blue">difficult</font>ies</font> as a result of the <font color="blue">uncertainties</font>     inherent  in  doing business in a <font color="blue">foreign country</font>, including economic,     political  and  regulatory <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>If there are <font color="blue"><font color="blue">difficult</font>ies</font> or     problems in our Mexico <font color="blue">facility</font>, or other <font color="blue">disruption</font>s in our production and     delivery process affecting product <font color="blue">availability</font>, these <font color="blue"><font color="blue">difficult</font>ies</font> could     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [43]Table of <font color="blue">Contents       </font>If one of our <font color="blue">products proves</font> to be defective or is <font color="blue">misused by</font> a <font color="blue">health care</font>     <font color="blue">practitioner</font> or patient, we may be subject to claims of <font color="blue">liability</font> that could     <font color="blue">adversely</font> affect our <font color="blue">financial condition</font> and the results of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A defect in the design or <font color="blue">manufacture</font> of our products, or a failure of our     products to perform for the use that we specify, could have a material     adverse effect on our reputation in the industry and subject us to claims of     <font color="blue">liability</font>  for  injuries  and  otherwise</td>
    </tr>
    <tr>
      <td>Misuse  of our product by a     <font color="blue">practitioner</font> or patient that results in injury could similarly subject us to     claims of <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We currently have in place product <font color="blue">liability</font> insurance     in the amount of dlra10 million for <font color="blue">liability</font> losses, including <font color="blue">legal defense</font>     costs</td>
    </tr>
    <tr>
      <td>Any substantial <font color="blue">underinsured loss would</font> have a material adverse     effect on our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore,     any <font color="blue">impairment</font> of our reputation could have a material adverse effect on our     sales, revenues, and prospects for future business</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> our <font color="blue">proprietary technology</font> and the patents, copyrights,     and  <font color="blue">trademarks</font>  that protect our products</td>
    </tr>
    <tr>
      <td>If <font color="blue">competitors</font> are able to     <font color="blue">independently</font> develop products of equivalent or superior <font color="blue">capabilities</font>, the     results of our <font color="blue">operations</font> could be <font color="blue"><font color="blue">adversely</font> impact</font>ed</td>
    </tr>
    <tr>
      <td>We rely <font color="blue">substantially</font> on <font color="blue">proprietary technology</font> and <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">filed patent applications</font> in the <font color="blue">United States </font>for <font color="blue">substantially</font> all of our     products</td>
    </tr>
    <tr>
      <td>We have also filed for <font color="blue">intellectual property rights protection</font> in     all <font color="blue">foreign countries</font> for <font color="blue">products from which</font> we expect <font color="blue">significant</font> revenue</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we held 130 patents, including <font color="blue">approximately</font> 40     <font color="blue">United States </font>patents and <font color="blue">approximately</font> 90 foreign patents</td>
    </tr>
    <tr>
      <td>Our patents     <font color="blue">generally</font>  expire  between  2006  and 2023</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">patents on</font> our     <font color="blue">elastomeric</font>  <font color="blue">balloon pump</font> and <font color="blue">Soaker Catheter </font>expire in 2011 and 2019,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Without <font color="blue">sufficient intellectual property protection</font>, our     <font color="blue">competitors</font> may be able to <font color="blue">sell products</font> identical to ours and cause a     <font color="blue">downward pressure on</font> the <font color="blue">selling price</font> of our products</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">pending patent</font> or <font color="blue">trademark applications will</font>     be approved or that any <font color="blue">patents will provide competitive advantages</font> for our     products or will not be challenged or circumvented by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> may also <font color="blue">independently</font> develop <font color="blue">products with equivalent</font> or     superior <font color="blue">capabilities</font> or otherwise obtain access to our <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In     addition, we <font color="blue">may become involved</font> in <font color="blue">potential litigation involving</font> our     <font color="blue">proprietary technology</font>, such as patents or <font color="blue">copyrights infringement</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">negative outcome from such proceedings may</font> have a material adverse effect on     our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our sales is to customers in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>We     may  lose  revenues,  market  share,  and <font color="blue">profits due</font> to <font color="blue">exchange rate</font>     <font color="blue">fluctuations</font> and other factors related to our foreign business</td>
    </tr>
    <tr>
      <td>For  the  year  ended <font color="blue">December </font>31, 2005, sales to customers in foreign     countries comprised <font color="blue">approximately</font> 13prca of our revenues</td>
    </tr>
    <tr>
      <td>Our foreign business     is subject to economic, political and regulatory <font color="blue">uncertainties</font> and risks     that are unique to each area of the world</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in <font color="blue">exchange rate</font>s     may also affect the prices that our foreign customers are willing to pay,     and  may put us at a price <font color="blue">disadvantage</font> compared to other <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potentially </font>volatile shifts in <font color="blue">exchange rate</font>s may <font color="blue">negatively</font> affect our     <font color="blue">financial condition</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stockholders</font>’ equity may also be <font color="blue"><font color="blue">adversely</font> affected</font> by unfavorable     <font color="blue">translation <font color="blue">adjustments</font></font> arising <font color="blue">from differences</font> in <font color="blue">exchange rate</font>s from     period to period</td>
    </tr>
    <tr>
      <td>In addition, we have not and currently do not hedge or     <font color="blue">enter into derivative contracts</font> in an effort to <font color="blue">address foreign exchange</font>     risk</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely on two <font color="blue">distributors</font></font> for a <font color="blue">significant</font> percentage of our     sales</td>
    </tr>
    <tr>
      <td>If our <font color="blue">relationship</font> with these <font color="blue">distributors</font> were to <font color="blue">deteriorate</font>, our     <font color="blue">sales may materially decline</font></td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, sales to B Braun Medical SA and B     Braun Medical Inc</td>
    </tr>
    <tr>
      <td>accounted for 7prca and 6prca of the Company’s <font color="blue">total revenues</font>,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">deterioration</font> in our <font color="blue">relationship</font> with B Braun Medical     SA or B Braun Medical Inc</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [44]Table of <font color="blue">Contents       </font>The <font color="blue">preparation</font> of our <font color="blue">financial statements</font> in <font color="blue"><font color="blue">accordance</font> with <font color="blue">accounting</font></font>     principles <font color="blue">generally</font> accepted in the <font color="blue">United States </font>requires us to make     estimates,  judgments, and <font color="blue">assumptions</font> that <font color="blue">may ultimately prove</font> to be     incorrect</td>
    </tr>
    <tr>
      <td>The <font color="blue">accounting</font> estimates and judgments that <font color="blue">management</font> must make in the     ordinary  course of business affect the reported amounts of assets and     <font color="blue">liabilities</font> at the date of the <font color="blue">financial statements</font> and the reported amounts     of revenue and <font color="blue">expenses during</font> the <font color="blue">periods presented</font></td>
    </tr>
    <tr>
      <td>If the underlying     estimates are ultimately proven to be incorrect, subsequent <font color="blue">adjustments</font>     resulting from errors could have a material adverse effect on our operating     results  for  the period or periods in which the change is identified</td>
    </tr>
    <tr>
      <td>Additionally, subsequent <font color="blue">adjustments</font> from errors could require us to restate     our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Restating </font><font color="blue">financial statements</font> could result in a     material decline in the price of our stock</td>
    </tr>
    <tr>
      <td>Failure to achieve and maintain <font color="blue">effective</font> <font color="blue">internal controls</font> in <font color="blue">accordance</font>     with Section 404 of the Sarbanes-Oxley Act could have a material adverse     effect on our business and our stock price</td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act requires us to <font color="blue">evaluate annually</font> the     <font color="blue">effective</font>ness of our <font color="blue"><font color="blue">internal controls</font> over</font> financial reporting as of the     end of <font color="blue">each fiscal year</font> and to include a <font color="blue">management</font> report assessing the     <font color="blue">effective</font>ness of our <font color="blue"><font color="blue">internal controls</font> over</font> financial reporting in all     annual reports</td>
    </tr>
    <tr>
      <td>Section 404 also requires our <font color="blue">independent auditor</font> to attest     to, and to report on, <font color="blue">management</font>’s assessment of our <font color="blue"><font color="blue">internal controls</font> over</font>     financial reporting</td>
    </tr>
    <tr>
      <td>Our <font color="blue">management</font> evaluated our <font color="blue"><font color="blue">internal controls</font> over</font>     financial  reporting  as  of <font color="blue">December </font>31, 2005 in order to <font color="blue">comply with</font>     Section 404  and  concluded  that our <font color="blue"><font color="blue">internal controls</font> over</font> financial     reporting were <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>However, in the year ended <font color="blue">December </font>31, 2004, we     identified  a  material weakness and our <font color="blue">independent registered public</font>     <font color="blue">accounting</font> firm expressed an <font color="blue">adverse opinion on</font> the <font color="blue">effective</font>ness of our     <font color="blue"><font color="blue">internal controls</font> over</font> financial reporting</td>
    </tr>
    <tr>
      <td>We have <font color="blue">since resolved</font> the     material  weakness,  but if we fail to implement and maintain adequate     internal  controls  in  the  future,  as  <font color="blue">such standards</font> are modified,     supplemented or <font color="blue">amended from</font> time to time, we <font color="blue">cannot assure</font> you that we or     our independent <font color="blue">accounting</font> firm will be able to conclude in the future that     we have <font color="blue">effective</font> <font color="blue"><font color="blue">internal controls</font> over</font> financial reporting in <font color="blue">accordance</font>     with Section 404</td>
    </tr>
    <tr>
      <td>If we fail to achieve and maintain a system of <font color="blue">effective</font>     <font color="blue">internal controls</font>, it could have a material adverse effect on our business     and our stock price</td>
    </tr>
    <tr>
      <td>RISK FACTORS RELATED SPECIFICALLY TO OUR COMMON STOCK     The <font color="blue">average trading volume</font> for our <font color="blue">common stock</font> is <font color="blue"><font color="blue">relatively</font> low</font> when     compared to <font color="blue">most larger companies</font></td>
    </tr>
    <tr>
      <td>As a result, there may be less liquidity     and more <font color="blue">volatility</font> associated with our <font color="blue">common stock</font>, even if our business     is doing well</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> has <font color="blue">been traded publicly since</font> <font color="blue">February </font>13, 1990, and since     then has had only a <font color="blue">few market makers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">average daily trading volume</font> for     our shares during the month of <font color="blue">February </font>2006 was <font color="blue">approximately</font> 295cmam000     shares</td>
    </tr>
    <tr>
      <td>There can be no assurance that a more active or <font color="blue">established trading</font>     market  for  our  common  stock will develop or, if developed, will be     maintained</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has been and is likely to continue to     be  <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Market prices for securities of <font color="blue">biotechnology</font> and     medical device companies, including ours, have <font color="blue">historically been highly</font>     volatile, and the market has from time to time experienced <font color="blue">significant</font> price     and volume <font color="blue">fluctuations</font> that appear unrelated to the operating performance     of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>The following factors, among others, can have a     <font color="blue">significant</font> effect on the <font color="blue">market price</font> of our securities:       •   <font color="blue">announcements</font> of <font color="blue">technological</font> innovations, new products, or clinical     <font color="blue">studies by us</font> or others;         •   <font color="blue">government regulation</font>;         •   changes in the coverage or <font color="blue">reimbursement</font> rates of <font color="blue">private insurers</font> and     <font color="blue"><font color="blue">governmental</font> agencies</font>;         •   <font color="blue">development</font>s in patent or other <font color="blue">proprietary rights</font>;         •   <font color="blue">future sales</font> of substantial amounts of our <font color="blue">common stock</font> by existing     <font color="blue">stockholders</font> or by us; and         •   <font color="blue">comments by securities analysts</font> and <font color="blue">general market conditions</font></td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________    [45]Table of <font color="blue">Contents       </font>The <font color="blue">realization</font> of any of the <font color="blue">risks described</font> in these “<font color="blue">Risk Factors</font>” could     also have a negative effect on the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Future sales of our <font color="blue">common stock</font> by existing <font color="blue">stockholders</font> could <font color="blue">negatively</font>     affect the <font color="blue">market price</font> of our stock and make it more <font color="blue">difficult</font> for us to     sell stock in the future</td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that such     <font color="blue">sales could</font> occur, could result in a decline in the <font color="blue">market price</font> of our     <font color="blue">common stock</font> and make it more <font color="blue">difficult</font> for us to complete <font color="blue">future equity</font>     <font color="blue">financings</font></td>
    </tr>
    <tr>
      <td>A substantial number of shares of our <font color="blue">common stock</font> and shares of     <font color="blue">common stock</font> subject to <font color="blue">outstanding options</font> and <font color="blue">warrants may</font> be resold     pursuant to currently <font color="blue">effective</font> registration statements</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31,     2005, there were:     •   22cmam628cmam657 shares of <font color="blue">common stock</font> that are <font color="blue">freely tradable</font> in the public     markets;       •   215cmam109 shares of <font color="blue">common stock</font> underlying outstanding warrants which     have <font color="blue">been registered</font> for <font color="blue">resale under</font> a <font color="blue">Registration Statement </font>on Form S-3     (Registration Nodtta 333-109096); and       •   an aggregate of 4cmam153cmam912 shares of <font color="blue">common stock</font> that may be issued on     the exercise of <font color="blue">stock options outstanding under</font> our <font color="blue">equity incentive</font> plans</td>
    </tr>
    <tr>
      <td>We cannot estimate the number of shares of <font color="blue">common stock</font> that <font color="blue">may actually</font> be     resold in the <font color="blue">public market</font> because this <font color="blue">will depend on</font> the <font color="blue">market price</font> for     our <font color="blue">common stock</font>, the individual <font color="blue">circumstances</font> of the sellers, and other     factors</td>
    </tr>
    <tr>
      <td>If  <font color="blue">stockholders</font>  sell large portions of their holdings in a     <font color="blue">relatively</font> short time, for liquidity or other reasons, the <font color="blue">market price</font> of     our <font color="blue">common stock</font> could decline <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Anti-takeover <font color="blue">devices may prevent</font> a sale, or changes in the <font color="blue">management</font>, of     I-Flow</td>
    </tr>
    <tr>
      <td>We have in place several anti-takeover devices, including a stockholder     rights plan, that may have the effect of delaying or preventing a sale, or     changes in the <font color="blue">management</font>, of the I-Flow</td>
    </tr>
    <tr>
      <td>For example, one anti-takeover     device  provides for a board of <font color="blue">directors</font> that is <font color="blue">separated into three</font>     classes, with their terms in <font color="blue">office staggered over three year periods</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>has the effect of delaying a change in control of the board of <font color="blue">directors</font>     without the <font color="blue">cooperation</font> of the <font color="blue">incumbent board</font></td>
    </tr>
    <tr>
      <td>In addition, our bylaws do     not allow <font color="blue">stockholders</font> to call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font> or act by     <font color="blue">written consent</font>, and also require <font color="blue">stockholders</font> to <font color="blue">give written</font> notice of any     proposal or <font color="blue">director nomination</font> to us within a <font color="blue">specified period</font> of time     prior to any <font color="blue">stockholder meeting</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may also issue shares</font> of <font color="blue">preferred stock without stockholder approval</font> and     on  terms that our board of <font color="blue">directors</font> may determine in the future</td>
    </tr>
    <tr>
      <td>The     issuance  of  preferred  stock could have the effect of making it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our <font color="blue">outstanding stock</font>,     and  the  holders of <font color="blue">such preferred stock could</font> have voting, dividend,     <font color="blue">liquidation</font>, and other rights superior to those of holders of our common     stock</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">pay dividends</font> and this may <font color="blue">negatively</font> affect the price of our     stock</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">paid <font color="blue">dividends on</font></font> our <font color="blue">common stock</font> and do not anticipate paying     <font color="blue">dividends on</font> our <font color="blue">common stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">future price</font> of     our <font color="blue">common stock</font> may be <font color="blue"><font color="blue">adversely</font> impact</font>ed because we do not <font color="blue">pay dividends</font></td>
    </tr>
    <tr>
      <td>In the future, our <font color="blue">common stock</font> may be removed from <font color="blue">listing on</font> <font color="blue">the Nasdaq     </font><font color="blue">quotation system</font> and may not qualify for <font color="blue">listing on</font> any <font color="blue">stock exchange</font>, in     which case it may be <font color="blue">difficult</font> to find a market in our stock</td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> is <font color="blue">no longer traded on</font> a <font color="blue">national trading market</font>, it may     be more <font color="blue">difficult</font> for you to <font color="blue">sell shares</font> that you own, and the price of our     <font color="blue">common stock</font> would likely be <font color="blue">negatively</font> affected</td>
    </tr>
    <tr>
      <td>Currently, our common     stock  is traded on the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>Nasdaq has a number of     continued  listing  <font color="blue">requirement</font>s,  including  a  <font color="blue">minimum trading price</font>     <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> <font color="blue">any Nasdaq </font>continued listing <font color="blue">requirement</font>     could cause our <font color="blue">common stock</font> to be removed from <font color="blue">listing on</font> Nasdaq</td>
    </tr>
    <tr>
      <td><font color="blue">Should     </font>this occur, we may not be able to secure <font color="blue">listing on</font> other exchanges or     <font color="blue">quotation system</font>s, and this would have a material adverse effect on the     price and liquidity of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>